Efficacy and safety of <scp>ME3183</scp> , an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis
Bibliographic record
Abstract
BACKGROUND: There is an unmet need for oral psoriasis medications with improved efficacy and safety. OBJECTIVES: We evaluated the efficacy and safety of oral ME3183, a novel phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis. METHODS: This was a randomized, double-blind, placebo-controlled study with a 16-week double-blind treatment period. Patients were randomly assigned (1:1:1:1:1) to oral ME3183 5 mg twice daily (BID), 10 mg once daily (QD), 7.5 mg BID, 15 mg QD or placebo. RESULTS: In total, 132 patients were randomly assigned to ME3183 5 mg BID (26 patients), 10 mg QD (26 patients), 7.5 mg BID (26 patients), 15 mg QD (27 patients) and placebo (27 patients). The proportions of patients achieving ≥75% reduction in baseline Psoriasis Area and Severity Index scores at Week 16 (primary endpoint) were 58.3%, 32.0%, 61.5% and 52.0% in each ME3183 group, respectively, versus 14.8% in the placebo group (all p < 0.01 vs. placebo, except for the 10 mg QD group). The most common adverse events across the ME3183 groups were diarrhoea (16.0%-38.5%), nausea (7.7%-30.8%) and headache (7.7%-42.3%). CONCLUSIONS: ME3183 should be further investigated as a safe and effective treatment alternative for moderate to severe plaque psoriasis.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".